ImmuPharma (LON:IMM) Shares Up 33.9% - Still a Buy?

Key Points

• ImmuPharma's shares surged by 33.9% on Tuesday, hitting a high of GBX 11.35 ($0.15), with trading volume increasing by 507% compared to its average.
• The company has a market capitalization of £54.02 million, with a significantly high price-to-earnings ratio of -1,214.61.
• ImmuPharma is focused on developing peptide-based therapeutics, with its lead program, P140 (Lupuzor™), aimed at treating autoimmune diseases like Lupus.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) were up 33.9% on Tuesday . The stock traded as high as GBX 11.35 ($0.15) and last traded at GBX 10.79 ($0.15). Approximately 45,884,684 shares were traded during mid-day trading, an increase of 507% from the average daily volume of 7,553,625 shares. The stock had previously closed at GBX 8.06 ($0.11).

ImmuPharma Trading Up 34.1%

The firm has a market capitalization of £54.02 million, a price-to-earnings ratio of -1,214.61 and a beta of 1.53. The stock has a fifty day moving average price of GBX 2.38 and a 200-day moving average price of GBX 2.70.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. On average, equities analysts expect that ImmuPharma plc will post -339.0000022 EPS for the current year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.